Trastuzumab

Drug Profile

Trastuzumab

Alternative Names: Anti-c-erbB-2 monoclonal antibody; Anti-erbB-2- monoclonal antibody; Anti-HER-2 monoclonal antibody; Anti-p185HER-2 monoclonal antibody; HER-2; HER-2 human monoclonal antibody; HER-2 MAb; HER-2 monoclonal antibody; HER-2 murine monoclonal antibody; HER-2/neu MAb; HER-2/neu monoclonal antibody; Herceptin; Monoclonal antibody 4D5; R 597; RG597

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Genentech; Memorial Sloan-Kettering Cancer Center
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Northwestern University; Roche; Sanofi; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer
  • Phase II Colorectal cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer

Most Recent Events

  • 06 Dec 2016 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Aug 2016 Phase-III clinical trials in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV) (NCT02896855)
  • 16 Apr 2016 Pharmacokinetics, efficacy and adverse event data from a phase III trial presented at 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top